Insider Transactions in Q2 2025 at Harrow Health, Inc. (HROW)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,000
-3.85%
|
$130,000
$26.59 P/Share
|
|
May 12
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-7.14%
|
$250,000
$25.9 P/Share
|
|
Apr 07
2025
|
John P. Saharek CEO & President, ImprimisRx |
SELL
Payment of exercise price or tax liability
|
Direct |
109,475
-18.98%
|
$2,517,925
$23.09 P/Share
|
|
Apr 07
2025
|
Andrew R. Boll Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
136,745
-14.95%
|
$3,145,135
$23.09 P/Share
|
|
Apr 07
2025
|
Mark L Baum Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
300,363
-10.36%
|
$6,908,349
$23.09 P/Share
|
|
Apr 03
2025
|
John P. Saharek CEO & President, ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
277,200
+32.46%
|
-
|
|
Apr 03
2025
|
Andrew R. Boll Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
346,500
+27.48%
|
-
|
|
Apr 03
2025
|
Mark L Baum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
762,300
+20.82%
|
-
|